<p>Bioventus, Inc. 最近召開了第三季度財報電話會議，整體情緒積極。公司報告了顯著的有機增長、盈利能力改善以及在新市場的戰略進展。此外，Bioventus 展現了有效的現金和債務管理。然而，由於之前的剝離和外匯損失，公司面臨了一些挑戰。</p>
<h2>有機收入增長</h2>
<p>Bioventus 報告第三季度有機收入增長了令人印象深刻的 8%。這一增長在所有業務部門均有體現，達到了中低個位數到低雙位數的增長。公司在這些領域的市場表現優於同行，突顯了其強大的競爭地位和有效的增長策略。</p>
<h2>調整後 EBITDA 和利潤率擴張</h2>
<p>公司調整後的 EBITDA 增長了 13%，利潤率擴張超過 200 個基點。這一改善凸顯了 Bioventus 的運營效率以及通過戰略舉措提升盈利能力的能力。</p>
<h2>自由現金流加速</h2>
<p>Bioventus 的自由現金流顯著加速，第三季度的運營現金幾乎是去年同期的三倍。公司實現了超過 100% 的現金轉化率，表明其財務健康狀況良好，現金管理實踐有效。</p>
<h2>外周神經刺激和 PRP 開發</h2>
<p>StimTrial 和 TalisMann 的推出在獲得 FDA 批准後獲得了積極反饋，新 PRP 系統 Excel 也同樣受到好評。Bioventus 預計這些創新將在 2026 年之前為盈利增長貢獻 200 個基點，突顯了公司在推進產品供應方面的承諾。</p>
<h2>減債</h2>
<p>在本季度，Bioventus 成功減少了 1900 萬美元的債務，並計劃在年底前將淨槓桿降低到 2.5 倍以下。這一減債的重點反映了公司加強資產負債表和提升財務穩定性的戰略方法。</p>
<h2>剝離和外匯影響</h2>
<p>儘管增長積極，Bioventus 的收入與去年相比保持不變，原因是其先進康復業務的剝離。此外，外匯匯率的不利影響導致了 50 萬美元的意外損失，給公司的財務表現帶來了挑戰。</p>
<h2>前瞻性指導</h2>
<p>Bioventus 重申了其全年指導，強調其強勁的第三季度表現。公司報告第三季度收入為 1.39 億美元，反映出 8% 的有機增長。調整後的 EBITDA 增長了 13%，達到 2700 萬美元，利潤率擴張超過 200 個基點。調整後的每股收益激增 200%，達到 0.15 美元。Bioventus 仍然有望實現全年調整後 EBITDA 利潤率擴張 100 個基點，並計劃調整後的每股收益在 0.64 到 0.68 美元之間。公司還強調了在疼痛治療業務中的戰略增長機會，預計到 2026 年將為盈利增長帶來 200 個基點的提升。</p>
<p>總之，Bioventus 的第三季度財報電話會議反映了積極的情緒，得益於顯著的有機增長、盈利能力改善和戰略進展。儘管面臨剝離和外匯損失的挑戰，公司展現了有效的現金和債務管理。展望未來，Bioventus 對其增長前景和財務表現保持樂觀，專注於核心業務領域的戰略機會。</p>

<p>Bioventus, Inc. 報告了強勁的第三季度業績， organic revenue 增長了 8%，調整後的 EBITDA 上升了 13%，自由現金流顯著加速。該公司成功減少了 1900 萬美元的債務，並計劃將淨槓桿降低至 2.5 倍以下。儘管面臨剝離和外匯損失的挑戰，Bioventus 仍然保持樂觀，重申其全年指引，預計調整後的每股收益在 0.64 美元至 0.68 美元之間，並專注於疼痛治療的戰略增長機會</p>

<p>Bioventus, Inc. recently held its third-quarter earnings call, which was marked by a positive sentiment overall. The company reported significant organic growth, improvements in profitability, and strategic advancements in new markets. Additionally, Bioventus demonstrated effective cash and debt management. However, the company faced challenges due to prior divestitures and foreign exchange losses.</p>
<div class="lb-trans"><p>Bioventus, Inc. 最近召開了第三季度財報電話會議，整體情緒積極。公司報告了顯著的有機增長、盈利能力改善以及在新市場的戰略進展。此外，Bioventus 展現了有效的現金和債務管理。然而，由於之前的剝離和外匯損失，公司面臨了一些挑戰。</p>
</div><h2>Organic Revenue Growth</h2>
<div class="lb-trans"><h2>有機收入增長</h2>
</div><p>Bioventus reported an impressive 8% increase in third-quarter revenue on an organic basis. This growth was observed across all business segments, achieving mid-single-digit to low double-digit increases. The company’s ability to outperform the market in these segments highlights its strong competitive position and effective growth strategies.</p>
<div class="lb-trans"><p>Bioventus 報告第三季度有機收入增長了令人印象深刻的 8%。這一增長在所有業務部門均有體現，達到了中低個位數到低雙位數的增長。公司在這些領域的市場表現優於同行，突顯了其強大的競爭地位和有效的增長策略。</p>
</div><h2>Adjusted EBITDA and Margin Expansion</h2>
<div class="lb-trans"><h2>調整後 EBITDA 和利潤率擴張</h2>
</div><p>The company saw a 13% rise in adjusted EBITDA, accompanied by a margin expansion of over 200 basis points. This improvement underscores Bioventus’s operational efficiencies and its ability to enhance profitability through strategic initiatives.</p>
<div class="lb-trans"><p>公司調整後的 EBITDA 增長了 13%，利潤率擴張超過 200 個基點。這一改善凸顯了 Bioventus 的運營效率以及通過戰略舉措提升盈利能力的能力。</p>
</div><h2>Free Cash Flow Acceleration</h2>
<div class="lb-trans"><h2>自由現金流加速</h2>
</div><p>Bioventus experienced a significant acceleration in free cash flow, with cash from operations nearly tripling in the third quarter compared to the previous year. The company achieved a cash conversion ratio of over 100%, indicating strong financial health and effective cash management practices.</p>
<div class="lb-trans"><p>Bioventus 的自由現金流顯著加速，第三季度的運營現金幾乎是去年同期的三倍。公司實現了超過 100% 的現金轉化率，表明其財務健康狀況良好，現金管理實踐有效。</p>
</div><h2>Peripheral Nerve Stimulation and PRP Development</h2>
<div class="lb-trans"><h2>外周神經刺激和 PRP 開發</h2>
</div><p>The launch of StimTrial and TalisMann, following FDA clearance, received positive feedback, as did the new PRP system, Excel. Bioventus anticipates these innovations will contribute to a 200 basis point increase in profitable growth by 2026, highlighting the company’s commitment to advancing its product offerings.</p>
<div class="lb-trans"><p>StimTrial 和 TalisMann 的推出在獲得 FDA 批准後獲得了積極反饋，新 PRP 系統 Excel 也同樣受到好評。Bioventus 預計這些創新將在 2026 年之前為盈利增長貢獻 200 個基點，突顯了公司在推進產品供應方面的承諾。</p>
</div><h2>Debt Reduction</h2>
<div class="lb-trans"><h2>減債</h2>
</div><p>During the quarter, Bioventus successfully reduced its debt by $19 million and plans to decrease net leverage below 2.5x by the end of the year. This focus on debt reduction reflects the company’s strategic approach to strengthening its balance sheet and enhancing financial stability.</p>
<div class="lb-trans"><p>在本季度，Bioventus 成功減少了 1900 萬美元的債務，並計劃在年底前將淨槓桿降低到 2.5 倍以下。這一減債的重點反映了公司加強資產負債表和提升財務穩定性的戰略方法。</p>
</div><h2>Impact of Divestiture and Foreign Exchange</h2>
<div class="lb-trans"><h2>剝離和外匯影響</h2>
</div><p>Despite the positive growth, Bioventus’s revenue remained unchanged compared to the prior year due to the divestiture of its advanced rehabilitation business. Additionally, foreign currency exchange rates had an unfavorable impact, resulting in a $0.5 million unplanned loss, posing a challenge to the company’s financial performance.</p>
<div class="lb-trans"><p>儘管增長積極，Bioventus 的收入與去年相比保持不變，原因是其先進康復業務的剝離。此外，外匯匯率的不利影響導致了 50 萬美元的意外損失，給公司的財務表現帶來了挑戰。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指導</h2>
</div><p>Bioventus reiterated its full-year guidance, emphasizing its robust third-quarter performance. The company reported a third-quarter revenue of $139 million, reflecting 8% organic growth. Adjusted EBITDA rose by 13% to $27 million, with a margin expansion of over 200 basis points. Adjusted earnings per share surged by 200% to $0.15. Bioventus remains on track to achieve a full-year adjusted EBITDA margin expansion of 100 basis points and aims for adjusted EPS between $0.64 to $0.68. The company also highlighted strategic growth opportunities in its pain treatments business, projecting a 200 basis point boost in profitable growth for 2026.</p>
<div class="lb-trans"><p>Bioventus 重申了其全年指導，強調其強勁的第三季度表現。公司報告第三季度收入為 1.39 億美元，反映出 8% 的有機增長。調整後的 EBITDA 增長了 13%，達到 2700 萬美元，利潤率擴張超過 200 個基點。調整後的每股收益激增 200%，達到 0.15 美元。Bioventus 仍然有望實現全年調整後 EBITDA 利潤率擴張 100 個基點，並計劃調整後的每股收益在 0.64 到 0.68 美元之間。公司還強調了在疼痛治療業務中的戰略增長機會，預計到 2026 年將為盈利增長帶來 200 個基點的提升。</p>
</div><p>In summary, Bioventus’s third-quarter earnings call reflected a positive sentiment, driven by significant organic growth, profitability improvements, and strategic advancements. Despite challenges from divestitures and foreign exchange losses, the company demonstrated effective cash and debt management. Looking forward, Bioventus remains optimistic about its growth prospects and financial performance, with a focus on strategic opportunities in its core business segments.</p>
<div class="lb-trans"><p>總之，Bioventus 的第三季度財報電話會議反映了積極的情緒，得益於顯著的有機增長、盈利能力改善和戰略進展。儘管面臨剝離和外匯損失的挑戰，公司展現了有效的現金和債務管理。展望未來，Bioventus 對其增長前景和財務表現保持樂觀，專注於核心業務領域的戰略機會。</p>
</div>

Bioventus, Inc. 報告第三季度盈利強勁增長